ICU Medical - ICUI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $207.50
  • Forecasted Upside: 24.17 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$167.11
▼ -4.62 (-2.69%)

This chart shows the closing price for ICUI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ICU Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICUI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICUI

Analyst Price Target is $207.50
▲ +24.17% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ICU Medical in the last 3 months. The average price target is $207.50, with a high forecast of $225.00 and a low forecast of $190.00. The average price target represents a 24.17% upside from the last price of $167.11.

This chart shows the closing price for ICUI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in ICU Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022KeyCorpLower Target$230.00 ➝ $225.00Low
8/9/2022Raymond JamesLower TargetOutperform$208.00 ➝ $190.00Low
8/3/2022KeyCorpLower TargetOverweight$265.00 ➝ $230.00Low
2/28/2022Raymond JamesLower TargetOutperform$286.00 ➝ $265.00High
10/22/2021KeyCorpLower TargetOverweight$302.00 ➝ $280.00Low
9/9/2021KeyCorpBoost TargetOverweight$225.00 ➝ $302.00Medium
9/9/2021Raymond JamesBoost TargetOutperform$220.00 ➝ $286.00Medium
8/6/2021KeyCorpLower TargetOverweight$236.00 ➝ $225.00Low
8/5/2021Raymond JamesLower TargetOutperform$245.00 ➝ $220.00Medium
2/26/2021Raymond JamesBoost TargetOutperform$235.00 ➝ $245.00High
2/11/2021Raymond JamesBoost TargetOutperform$210.00 ➝ $235.00Low
1/8/2021KeyCorpBoost TargetOverweight$222.00 ➝ $236.00Medium
12/17/2020Raymond JamesReiterated RatingBuyHigh
11/6/2020KeyCorpBoost TargetOverweight$218.00 ➝ $222.00Low
9/2/2020KeyCorpBoost TargetOverweight$199.00 ➝ $218.00Low
8/11/2020Raymond JamesLower TargetOutperform$228.00 ➝ $210.00High
5/13/2020KeyCorpLower TargetOverweight$206.00 ➝ $199.00High
5/8/2020Raymond JamesBoost TargetOutperform$215.00 ➝ $228.00High
3/31/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformMedium
3/18/2020KeyCorpUpgradeSector Weight ➝ Overweight$206.00High
2/28/2020Raymond JamesBoost TargetOutperform$203.00 ➝ $215.00High
11/12/2019Raymond JamesBoost TargetOutperform ➝ Positive$185.00 ➝ $203.00High
9/6/2019Raymond JamesSet TargetBuy$185.00Low
8/8/2019Raymond JamesDowngradeStrong-Buy ➝ OutperformHigh
3/1/2019Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$315.00 ➝ $300.00Low
10/17/2017KeyCorpInitiated CoverageSector WeightN/A
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/22/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/21/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
ICU Medical logo
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Read More

Today's Range

Now: $167.11
Low: $165.43
High: $171.30

50 Day Range

MA: $169.60
Low: $161.40
High: $188.10

52 Week Range

Now: $167.11
Low: $158.60
High: $282.00

Volume

199,561 shs

Average Volume

208,844 shs

Market Capitalization

$3.99 billion

P/E Ratio

397.89

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of ICU Medical?

The following Wall Street analysts have issued research reports on ICU Medical in the last twelve months: KeyCorp, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for ICUI.

What is the current price target for ICU Medical?

2 Wall Street analysts have set twelve-month price targets for ICU Medical in the last year. Their average twelve-month price target is $207.50, suggesting a possible upside of 24.2%. KeyCorp has the highest price target set, predicting ICUI will reach $225.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $190.00 for ICU Medical in the next year.
View the latest price targets for ICUI.

What is the current consensus analyst rating for ICU Medical?

ICU Medical currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICUI will outperform the market and that investors should add to their positions of ICU Medical.
View the latest ratings for ICUI.

What other companies compete with ICU Medical?

How do I contact ICU Medical's investor relations team?

ICU Medical's physical mailing address is 951 CALLE AMANECER, SAN CLEMENTE CA, 92763. The medical instruments supplier's listed phone number is (949) 366-2183 and its investor relations email address is [email protected] The official website for ICU Medical is www.icumed.com. Learn More about contacing ICU Medical investor relations.